Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wilson Therapeutics Appoints Chair

This article was originally published in Scrip

Executive Summary

Wilson Therapeutics AB., a privately held pharmaceutical company, has appointed Andrew Kay chair of its board of directors. Hugh Rienoff, the company's previous chair, will continue to advise the company as a consultant. Kay is currently advisor and chair to various biotech companies and most recently was CEO of Algeta, a publicly traded oncology company acquired by Bayer. He was previously global head of marketing and sales at Novartis, vice-president of marketing US at Zeneca and also held commercial positions in Europe with AstraZeneca, Eli Lilly, Sandoz and Boots.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts